Table 3.

Composition and characterization of niosomal formulations.

Formulation code	Surfactant grade	Surfactant : CHOL : DCP ratio	Mean vesicle diameter (μm)*	Zeta potential (mV)*	Entrapment efficiency (%)*	% Cumulative drug released (at the end of 24 hours)*
F1	Sorbitan laurate	2.5 : 1 : 0.1	7.12 ± 0.75	−91 ± 0.19	37 ± 0.56	—
F2		2 : 1 : 0.1	8.01 ± 0.61	−87 ± 0.13	48 ± 0.69	—
F3		1.5 : 1 : 0.1	8.70 ± 1.24	−56 ± 0.23	58 ± 0.42	—
F4		1 : 1 : 0.1	9.03 ± 0.76	−29 ± 0.12	78 ± 1.08	83.86 ± 3.72
F5		1 : 1.5 : 0.1	10.91 ± 0.86	−25 ± 0.15	75 ± 0.73	—
F6	Sorbitan monopalmitate	2.5 : 1 : 0.1	5.70 ± 0.75	−61 ± 0.16	38 ± 0.71	—
F7		2 : 1 : 0.1	7.84 ± 0.96	−52 ± 0.21	52 ± 0.82	—
F8		1.5 : 1 : 0.1	8.65 ± 0.81	−48 ± 0.24	63 ± 0.36	—
F9		1 : 1 : 0.1	8.90 ± 1.30	−26 ± 0.18	83 ± 0.71	94.12 ± 4.82
F10		1 : 1.5 : 0.1	9.85 ± 0.78	−22 ± 0.17	81 ± 0.37	—
F11	Sorbitan monostearate	2.5 : 1 : 0.1	3.98 ± 0.34	−46 ± 0.15	48 ± 0.52	—
F12		2 : 1 : 0.1	4.31 ± 0.67	−39 ± 0.17	59 ± 1.01	—
F13		1.5 : 1 : 0.1	4.93 ± 1.16	−28 ± 0.23	71 ± 0.65	—
F14		1 : 1 : 0.1	6.82 ± 0.76	−23 ± 0.21	95 ± 0.51	99.09 ± 4.78
F15		1 : 1.5 : 0.1	8.55 ± 0.86	−22 ± 0.18	89 ± 0.79	—
F16	Sorbitan oleate	2.5 : 1 : 0.1	2.95 ± 0.87	−45 ± 0.19	52 ± 0.63	—
F17		2 : 1 : 0.1	4.17 ± 0.86	−37 ± 0.20	62 ± 0.54	—
F18		1.5 : 1 : 0.1	4.59 ± 0.56	−25 ± 0.21	74 ± 0.74	—
F19		1 : 1 : 0.1	6.31 ± 0.75	−21 ± 0.11	96 ± 0.66	89.90 ± 3.99
F20		1 : 1.5 : 0.1	8.42 ± 0.65	−16 ± 0.14	89 ± 0.82	—

*The data were reported as an average of 3 measurements (mean ± S.D.).